TD SYNNEX Operating Cash Flow decreased by 161.3% to -$895.87M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 19.8%, from -$748.00M to -$895.87M. Over 3 years (FY 2021 to FY 2025), Operating Cash Flow shows an upward trend with a 21.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates strong operational efficiency and cash generation, while a decrease may signal operational challenges or issues with working capital management.
This metric represents the total cash generated or consumed by a company's core business operations during a specific pe...
Standard across all industries; peers in the medical device and diagnostics sector typically maintain high conversion ratios of net income to operating cash flow.
net_cash_from_operating| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $279.34M | $0.00 | $561.00M | -$1.32B | -$67.31M | -$102.80M | $707.55M | $591.96M | $210.67M | $384.71M | $0.00 | $385.78M | $561.94M | -$748.00M | $573.18M | $246.14M | $1.46B | -$895.87M |
| QoQ Change | — | -100.0% | — | -335.4% | +94.9% | -52.7% | +788.3% | -16.3% | -64.4% | +82.6% | -100.0% | — | +45.7% | -233.1% | +176.6% | -57.1% | +493.3% | -161.3% |
| YoY Change | — | — | — | — | — | +92.2% | — | +979.4% | — | +474.2% | -100.0% | -34.8% | +166.7% | -294.4% | — | -36.2% | +159.9% | -19.8% |